DR. GUOFENG XIE, MD
Osteopathic Medicine at Greene St, Baltimore, MD
License number
Maryland D62219
Category
Osteopathic Medicine
Type
Gastroenterology
Address
Address
22 S Greene St, Baltimore, MD 21201
Phone
(410) 328-5793
(410) 328-0248 (Fax)
(410) 328-0248 (Fax)
Personal information
See more information about GUOFENG XIE at radaris.comName
Address
Phone
8 Crestleigh Pl, Lutherville, MD 21093
6012 Hunt Ridge Rd, Baltimore, MD 21210
8 Crestleigh Pl, Lutherville Timonium, MD 21093
Organization information
See more information about GUOFENG XIE at bizstanding.comGuofeng Xie MD,MBBS
22 S Greene St, Baltimore, MD 21201
Industry:
Internist
Phone:
(410) 328-5196 (Phone)
Guofeng Xie
Professional information
Dr. Guofeng Xie, Baltimore MD - MD (Doctor of Medicine)
Specialties:
Gastroenterology
Address:
22 S Greene St SUITE N3W62, Baltimore 21201
(410) 328-2454 (Phone), (410) 328-0267 (Fax)
(410) 328-2454 (Phone), (410) 328-0267 (Fax)
Certifications:
Gastroenterology, 2008, Internal Medicine, 2005
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
22 S Greene St SUITE N3W62, Baltimore 21201
University of Maryland Medical Center
22 South Greene St, Baltimore 21201
University of Maryland Medical Center
22 South Greene St, Baltimore 21201
Education:
Medical School
Beijing Med University Beijing Beijing China
Graduated: 1990
Beijing Med University Beijing Beijing China
Graduated: 1990
Treatment Of Cancer With Anti-Muscarinic Receptor Agents
US Patent:
2009001, Jan 8, 2009
Filed:
Apr 24, 2008
Appl. No.:
12/109156
Inventors:
Jean-Pierre Raufman - Baltimore MD, US
Kunrong Cheng - Cockeysville MD, US
Jasleen Shant - Elkridge MD, US
Guofeng Xie - Baltimore MD, US
Sandeep Khurana - Columbia MD, US
Kunrong Cheng - Cockeysville MD, US
Jasleen Shant - Elkridge MD, US
Guofeng Xie - Baltimore MD, US
Sandeep Khurana - Columbia MD, US
Assignee:
University of Maryland, Baltimore - Baltimore MD
International Classification:
A61K 39/395, A61P 35/00, A61K 31/7088, A01K 67/027, A61K 31/713
US Classification:
4241301, 514 44, 800 18
Abstract:
The present invention relates to methods of treating proliferative disorders of colon cells. The methods comprise administering to the cells an effective amount of at least one agent to reduce M3 muscarinic receptor-mediated transactivation of at least one epidermal growth factor receptor.